Diagnostic and therapeutic epitope, and transgenic plant
View Patent ↗A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62 PQPELPY 68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.
1. A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognised by a T cell receptor or an antibody that recognises an epitope comprising SEQ ID NO:1 or SEQ ID NO:2, wherein the peptide analogue comprises:
Pro-Gln-Pro-Xaa-Leu-Pro-Tyr (SEQ ID NO:79), wherein Xaa is Asp; or
Xaa-Gln-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:80), wherein Xaa is Val; or
Pro-Xaa-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:81), wherein Xaa is Ser, Ile, or Met; or
Pro-Gln-Pro-Glu-Leu-Pro-Xaa (SEQ ID NO:85), wherein Xaa is Val.
2. A peptide analogue according to claim 1 wherein the peptide analogue comprises Pro-Gln-Pro-Xaa-Leu-Pro-Tyr (SEQ ID NO:79), wherein Xaa is Asp.
3. A peptide analogue according to claim 1 wherein the peptide analogue comprises:
Xaa-Gln-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:80), wherein Xaa is Val.
4. A peptide analogue according to claim 1 wherein the peptide analogue comprises:
Pro-Xaa-Pro-Glu-Leu-Pro-Tyr (SEQ ID NO:81), wherein Xaa is Ser, Ile, or Met.
5. A peptide analogue according to claim 1 wherein the peptide analogue comprises:
Pro-Gln-Pro-Glu-Leu-Pro-Xaa (SEQ ID NO:85), wherein Xaa is Val.
6. A peptide analogue according to claim 1 which comprises a non-natural amino acid at the N terminus or C terminus.
7. A composition comprising one or more of the peptide analogues according to claim 1 .
8. A pharmaceutical composition comprising a peptide analogue according to claim 1 and a pharmaceutically acceptable carrier or diluent.
9. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
a) contacting a sample from the individual with a peptide analogue according to claim 1 ; and
b) determining in vitro whether T cells in the sample recognise the peptide analogue, wherein recognition by the T cells indicates that the individual has or is susceptible to coeliac disease.
10. A method according to claim 9 wherein the sample is a blood sample.
11. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
a) administering a peptide analogue according to claim 1 to the skin of the individual; and
b) detecting the presence of inflammation at the site of administration, wherein detection of inflammation indicates that the T cells of the individual recognise the peptide analogue.
12. A method of treating coeliac disease in an individual comprising administering a peptide analogue according to claim 1 to the individual.
13. A kit comprising:
a peptide analogue according to claim 1 ; and
a means to detect the recognition of the peptide analogue by the T cell.
14. A fusion protein comprising a peptide analogue according to claim 1 and other gliadin or non-gliadin sequence.
15. A fusion protein according to claim 14 which comprises a non-natural amino acid at the N terminus or C terminus.
16. A composition comprising one or more of the fusion proteins according to claim 14 .
17. A pharmaceutical composition comprising a fusion protein according to claim 14 and a pharmaceutically acceptable carrier or diluent.
18. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
a) contacting a sample from the individual with a fusion protein according to claim 14 ; and
b) determining in vitro whether T cells in the sample recognise the fusion protein, wherein recognition by the T cells indicates that the individual has or is susceptible to coeliac disease.
19. A method according to claim 18 wherein the sample is a blood sample.
20. A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising:
a) administering a fusion protein according to claim 14 to the skin of the individual; and
b) detecting the presence of inflammation at the site of administration, wherein detection of inflammation indicates that the T cells of the individual recognise the fusion protein.
21. A method of treating coeliac disease in an individual comprising administering a fusion protein according to claim 14 to the individual.
22. A kit comprising:
a fusion protein according to claim 14 ; and
a means to detect the recognition of the fusion peptide by the T cell.